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Introduction: Fusions of the anaplastic lymphoma receptor
tyrosine kinase gene (ALK), ret proto-oncogene (RET), ROS
proto-oncogene 1, receptor tyrosine kinase gene (ROS1), B-
Raf proto-oncogene, serine/threonine kinase gene (BRAF),
and neuregulin 1 gene (NRG1) and intronic MMNG HOS
Transforming gene (MET) mutations are druggable onco-
gene alterations in lung adenocarcinoma that cause
expression of aberrant transcripts. Because these aberrant
transcripts are both infrequent (incidence <5%) and
mutually exclusive, multiplex assays are required to detect
them in tumor samples.
Methods: Aberrant transcripts of the six aforementioned
oncogenes (36 transcripts in total) were examined in a
molecular counting (MC) assay, which counts RNA mole-
cules by simultaneous hybridization of several probes.
Forty-one samples of surgically resected lung adenocarci-
noma tissue found to express one of these aberrant onco-
genic transcripts upon whole transcriptome sequencing
(test cohort: n ¼ 22) or reverse transcription polymerase
chain reaction (validation cohort: n ¼ 19) analyses were
subjected to MC, after which biopsies were performed on
tumor tissue samples.
Results: Threshold values for the diagnosis of each of the
36 transcripts were determined in frozen and formalin-
ﬁxed parafﬁn-embedded samples from the test cohort. On
the basis of these threshold values, the MC assay diagnosed
expression of oncogenic transcripts in the validation cohort
samples with 100% accuracy. The assay also accuratelydetected oncogenic fusions in bronchial lavage ﬂuid and
transbronchial biopsy samples.
Conclusions: The MC assay allows multiplex detection of
oncogenic fusion and exon-skipped transcripts in tumor
samples, including in formalin-ﬁxed parafﬁn-embedded
samples obtained in the clinic.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Analyses of lung adenocarcinoma (LADC) genomes
have identiﬁed several oncogene alterations that cause
expression of aberrant transcripts in tumor cells. A
representative example is the fusion of oncogenes toJournal of Thoracic Oncology Vol. 11 No. 2: 203-212
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of protein kinases encoded by these oncogenes.1,2 These
alterations are a mutually exclusive driver mutation in
lung carcinogenesis and are a target for therapies based
on protein tyrosine kinase inhibitors (TKIs). A well-
known example is the oncogenic epidermal growth
factor receptor gene (EGFR) mutation, which is a target
for therapy using EGFR-TKIs. Indeed, LADCs harboring
the anaplastic lymphoma receptor tyrosine kinase gene
(ALK) oncogene fusion (in 3%–5% of all cases of LADC)
respond very well to ALK inhibitors such as crizotinib,3
ceritinib,4 and alectinib.5 Ret proto-oncogene (RET) and
ROS proto-oncogene 1, receptor tyrosine kinase gene
(ROS1) oncogene fusions are also rare (each occurring in
1%–3% of cases of LADC6–10), but they are a promising
target for therapy with TKIs. Several clinical trials
focusing on RET and ROS1 fusion–positive LADC have
been undertaken, and the results of these studies have
recently been reported.11,12 In addition, there is a report
of single patient with RET fusion–positive LADC who
responded to RET TKI.13 These reports indicate the
therapeutic effects of RET and ROS1 TKIs. Recently, we
and others identiﬁed B-Raf proto-oncogene, serine/
threonine kinase gene (BRAF) and neuregulin 1 gene
(NRG1) fusions as another therapeutic target in
approximately 10% of patients with invasive mucinous
LADC.14,15 Recent studies have also identiﬁed another
type of oncogene alteration that generates aberrant
oncogenic transcripts in approximately 3% of LADCs:
skipping of the coding exon 14 in MMNG HOS Trans-
forming gene (MET) oncogene transcripts on account of
aberrant splicing, which is associated mainly with
intronic mutations.16,17 The skipped transcript produces
a constitutively active MET protein lacking the E3
ubiquitin protein ligase (CBL) binding domain that
negatively regulates MET kinase. Indeed, in recent re-
ports, a MET TKI showed antitumor activity in patients
with LADCs expressing exon 14–skipped MET tran-
scripts,18,19 thus suggesting that this alteration is also a
promising therapeutic target.
Precision medicine for patients with LADC on the
basis of the TKIs described earlier requires the diagnosis
of multiplex oncogene aberrations in tumor cells. Because
the tumors of most patients subjected to TKI therapy are
inoperable, diagnosis must be performed by using small
amounts of ﬁxed formalin-ﬁxed and parafﬁn-embedded
(FFPE) biopsy samples or archived surgical specimens
for histopathological examination. In fact, techniques
such as ﬂuorescence in situ hybridization, which detects
gross chromosome rearrangements, are often used to
diagnose gene fusions in such clinical specimens. How-
ever, the recent discovery of a number of uncommon but
druggable oncogene fusions in LADC, along with the
ﬁnding that they are mutually exclusive, means thatmultiplex assays allowing simultaneous identiﬁcation of
several alterations are required. Furthermore, in contrast
to hot spot mutations such as EGFR, Kirsten rat sarcoma
viral gene homolog gene (KRAS), and BRAF (which acti-
vate oncogenes in tumor cell), the presence of highly
diverse genomic fusion points located within intron
sequences hampers the detection of gene fusions by
multiplex genome polymerase chain reaction (PCR)-
based assays using next-generation sequencers.20 In
addition, identifying the intronic mutations responsible
for MET exon skipping using genomic DNA is difﬁcult
because of their highly diverse locations and the occur-
rence of passenger mutations.21 Multiplex reverse tran-
scription (RT)-PCR–based assays using tumor RNA
are often used to detect aberrant transcripts caused by
gene fusions and exon skipping because there are
few aberrant transcript patterns, despite the diversity
with respect to the location of the responsible mutations.
However, the poor quality of the RNA obtained from
FFPE tumor tissues, particularly from archived tissues,
makes it difﬁcult to develop reliable RT-PCR–based
multiplex assays.
Molecular counting (MC) using the nCounter system
(NanoString Technologies, Seattle, WA) is a method of
quantifying RNA that is not based on RT and PCR; this
method directly counts RNA molecules by means of
simultaneous hybridization of multiple probes. Indeed,
previous studies have demonstrated the feasibility of
this method for quantifying RNA expression and
detecting gene fusions.22,23 Here, we used this method to
detect 36 oncogenic transcripts, 35 of which were
derived from ﬁve oncogenes (ALK, RET, ROS1, NRG1, and
BRAF) fused to partner genes and the aforementioned
MET exon–skipped transcript above. To examine the
feasibility of this method, RNA samples obtained from
62 LADC tissue samples from 41 patients (39 FFPE and
23 snap-frozen tissue samples in total; Fig. 1B) were
subjected to MC. These samples were selected from
608 consecutive patients with LADC patients because
whole RNA sequencing or RT-PCR analyses of snap-
frozen tissues revealed that they either did or did not
express aberrant oncogenic transcripts.Methods
Subjects
Consecutive patients with LADC who underwent
surgical resection between 1997 and 2008 at the Na-
tional Cancer Center Hospital in Tokyo (n ¼ 608) were
screened for EGFR, KRAS, BRAF, and HER2 hot spot
mutations by the high-resolution melting method using
genomic DNA obtained from snap-frozen tumor tis-
sues.24 RT-PCR of RNA obtained from snap-frozen tumor
tissues as described previously was used to examine the
Figure 1. (A) Selection of study subjects. From 608 consecutive patients who underwent surgical resection of lung adeno-
carcinoma, we selected 41 who harbored oncogenic gene fusions or exon skipping. Patients were classiﬁed into two cohorts.
Cases in which RNA isolated from snap-frozen tumor samples had been analyzed by whole transcriptome RNA sequencing
were included in the test cohort (n ¼ 22), whereas those in which RNA isolated from snap-frozen tumors samples had been
analyzed by reverse transcription polymerase chain reaction were included in the validation cohort (n ¼ 19). (B) Sample
characteristics and molecular counting assay results. RNAwas extracted from fresh frozen and/or formalin-ﬁxed and parafﬁn-
embedded tissues. Status was determined by counting the signals generated by fusion probes (F) or those generated by fusion
and imbalance probes (FI). (Black box) Diagnosis based on counts generated by the fusion probe only. (Gray box) Diagnosis
based on counts generated by the FI probes. (C) Strategy for diagnosing gene fusions and METexon skipping. (Left) Twenty-six
cases of gene fusion and one case of MET exon 14 skipping were diagnosed on the basis of counts generated by the fusion
probes alone. (Right) Nine cases of gene fusion were diagnosed on the basis of counts generated by both FI probes.
February 2016 Multiplex Diagnosis of Oncogenic Fusions 205following fusions: echinoderm microtubule associated
protein like 4 gene (EML4)-ALK and kinesin family
member 5B (KIF5B)-ALK; KIF5B-RET and coiled-coil
domain containing 6 gene (CCDC6)-RET; and CD74, ma-
jor histocompatibility complex, class II invariant chain
gene (CD74)-ROS1, ezrin gene (EZR)-ROS1, and solute
carrier family 34 (type II sodium/phosphate cotrans-
porter), member 2 gene (SLC34A2)-ROS1.8,10,25 Histo-
logical diagnosis was based on the latest edition of the
World Health Organization classiﬁcation of lung tu-
mors.26 RNA sequencing was performed on the 160
cases that yielded sufﬁcient RNA to determine whether
they expressed oncogene fusions and exon-skipped METtranscripts. The results were conﬁrmed by RT-PCR as
described previously.21
Sixty-four cases of LADC with ALK, RET, ROS1, NRG1,
and BRAF gene fusions or MET exon skipping (Fig. 1A)
were identiﬁed. After 23 cases been excluded because
of insufﬁcient sample, the remaining 41 were divided
into two cohorts and subjected to MC analysis. The
test cohort included 22 cases in which whole RNA
sequencing with next-generation sequencers had been
performed on RNA obtained from snap-frozen tumor
tissues. From these cases, 13 frozen tissue RNA samples
and 21 FFPE tissue RNA samples were available for
study (see Fig. 1B). The validation cohort comprised
206 Sunami et al Journal of Thoracic Oncology Vol. 11 No. 219 cases in which RT-PCR analysis had been performed
to determine the presence of ALK, RET, ROS1, NRG1,
and BRAF fusions and MET exon skipping. From these
cases, 10 frozen tissue RNA samples and 18 FFPE tissue
RNA samples were available for study (see Fig. 1B). In
addition, two FFPE tumor tissues that had been obtained
by transbronchial biopsy and diagnosed as positive
for the RET and ROS1 fusions, respectively, and 18
bronchial lavage samples (including two harboring
the EML4-ALK fusion) that had been obtained by endo-
bronchial ultrasound-guided transbronchial needle
aspiration were also tested by MC assay. This study
was approved by the institutional review board of the
National Cancer Center, and all patients gave written
informed consent.
In snap-frozen tissue samples, the percentage of tu-
mor cells was determined to range from 10% to 90%
(mean 22%) by using the Global Parameter Hidden
Markov Model method27 on the basis of somatic muta-
tion and allelic imbalance data as described previously.25
The results were consistent with those for the FFPE
tissue samples estimated by hematoxylin and eosin
staining. Thus, the percentage of tumor cells in the
samples in the present study was determined to be
higher than 10%.RNA Preparation
RNA was extracted from FFPE tissue sections (ﬁve
sections, each 5 mm thick) using the RNeasy FFPE
kit (QIAGEN, Hilden, Germany) or from lavage ﬂuid
using the RNeasy Mini kit (QIAGEN). Total RNA was
extracted from grossly dissected, snap-frozen tissue
samples using TRIzol (Invitrogen, Carlsbad, CA) ac-
cording to the manufacturer’s instructions. RNA was
quantiﬁed using the Nanodrop 8000 (Thermo Scien-
tiﬁc, Wilmington, DE).MC Analysis
The nCounter system uses a set of probes to detect
transcripts: a single 50 reporter probe (approximately
50-mer) linked to a ﬂuorescence bar code tag (6-mer)
and a biotinylated 30 capture probe (approximately
50-mer). Seventy sets of probes (Supplementary
Table 1) were designed to simultaneously detect 36
aberrant transcripts (i.e., 35 fusion transcripts for
ﬁve oncogenes and one exon 14-skipped MET tran-
script) (Table 1). The probes were synthesized by
NanoString Technologies (Seattle, WA). Of the 70 sets,
38 were designed to hybridize with chimeric portions
of the fusion transcripts, whereas the other 24 sets
were designed to hybridize with wild-type ALK, RET,
and NRG1 transcripts to examine gene fusion–induced
imbalances in the expression of the 50 and 30 regionsof the transcripts. Eight sets of probes were designed to
hybridize with internal control genes: glyceraldehyde-
3-phosphate dehydrogenase gene (GAPDH), omithine
decarboxylase antizymel gene (OAZ1), polymerase
(RNA) II (DNA directed) polypeptide A, 220lDa
gene (POLR2A), and glucuronidase, beta gene (GUSB).
The nCounter assay was performed according to
the manufacturer’s instructions. Brieﬂy, 150 ng and
400 ng of RNA from fresh frozen and FFPE tissues,
respectively, were used in the assay to ensure that the
counts for an internal control gene (GPADH) were
higher than 5000 per sample. RNA was hybridized
with the probe sets for 16 hours at 67C. Samples were
processed using an automated nCounter Sample Prep
Station (NanoString Technologies, Inc.). Cartridges
containing immobilized and aligned reporter com-
plexes were subsequently imaged on an nCounter
Digital Analyzer (NanoString Technologies, Inc.) that
had been set at a data resolution of 555 ﬁelds of view.
Reporter counts were collected and normalized using
nSolver analysis software version 2.0 (NanoString
Technologies, Inc.).Determination of Gene Fusion and Exon Skipping
Data were normalized in two steps as described pre-
viously.22 First, six positive internal controls were used to
remove potential systemic differences between individual
hybridization experiments. The sumof the signal intensity
(Si) from the six positive control probes was calculated
for sample i and then scaled using the normalization
factor, Smean/Si. Second, the scaled signal intensity of
sample iwas further normalized using four housekeeping
genes to remove any effects that might be attributable to
differences in the amount of input RNA. For example, if
Hi represents the genes in sample i, the second normali-
zation factor would be deﬁned as Hmean/Hi.
Previous studies have suggested that aberrations in
the six oncogenes examined herein are mutually exclu-
sive.28,29 This suggestion was supported by the whole
transcriptome sequencing results for the test cohort
samples examined; therefore, samples expressing one
particular aberrant oncogene transcript were used as
negative controls for the other aberrant oncogene tran-
scripts. The threshold values used to determine the
presence or absence of a particular aberrant transcript
were deﬁned as the mean plus ﬁve standard deviations
(SDs) above the value for tumor samples harboring ab-
errations in other transcripts. On the basis of these
threshold values, the rate of false-positive detection was
predicted to be less than 0.0002%. Threshold values
were set for both fresh frozen and FFPE tissues. To
determine imbalances in the expression of the 50 and 30
regions of gene transcripts, the 30 overexpression ratio
Table 1. Aberrant Transcripts for the Six Oncogenes Examined by Molecular Counting
Target
Oncogene
Fusion or Aberrant
Transcripts
Detectable
Variants
Cases in Test
Cohort, n
Cases in Validation
Cohort, n
Total Cases,
N
ALK EML4-ALK E13:A20 2 3 5
E20:A20 1 1 2
E6:A20 1 0 1
E2:A20 0 0 0
E18:A20 0 1 1
KIF5B-ALK K15:A20 0 0 0
K17:A20 0 0 0
K24:A20 0 0 0
TFG-ALK T6:A20 0 0 0
RET KIF5B-RET K15:R11 2 2 4
K15:R12 0 0 0
K16:R12 1 0 1
K22:R12 1 0 1
K23:R12 1 0 1
K24:R8 1 0 1
K24:R11 0 0 0
CCDC6-RET C1:R12 0 1 1
ROS1 CD74-ROS1 C6:R32 0 0 0
C6:R34 6 2 8
EZR-ROS1 E10:R34 1 2 3
SDC4-ROS1 S2:R32 0 0 0
S2:R34 0 0 0
S4:R32 0 0 0
S4:R34 0 0 0
SLC34A2-ROS1 S4:R32 0 0 0
S4:R34 0 0 0
S13del:R32 0 1 1
GOPC-ROS1 G8:R32 0 0 0
G8:R34 0 0 0
TPM3-ROS1 T8:R35 0 0 0
LRIG3-ROS1 L16:R35 0 0 0
BRAF TRIM24-BRAF T5:B8 1 0 1
T9:B9 0 0 0
NRG1 CD74-NRG1 C8:N6 0 2 2
C6:N6 1 0 1
MET Exon 14 skip M13:M15 3 4 7
Total 22 19 41
EML4, echinoderm microtubule associated protein like 4 gene; ALK, anaplastic lymphoma receptor tyrosine kinase gene; KIF5B, kinesin
family member 5B gene; TFG, TKK-fused gene; RET, Ret proto-oncogene; CCDC6, coiled-coil domain containing 6 gene; CD74, CD74, major
histocompatibility complex, class II invariant chain gene; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase gene; EZR, ezrin gene;
SDC4, syndecan 4 gene; SLC34A2, solute carrier family 34 (type II sodium/phosphate cotransporter), member 2 gene; GOPC, golgi-
associated PDZ and coiled-coil motif containing gene; TPM3, tropomyosin 3 gene; LRIG3, leucine-rich repeats and immunoglobulin-like
domains 3 gene; BRAF, B-Raf proto-oncogene, serine/threonine kinase gene; TRIM24, tripartite motif containing 24 gene; NRG1, neu-
regulin 1 gene; MET, MMNG HOS Transforming gene.
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50-imbalanced probe counts. Threshold values for 30
overexpression for a particular gene were deﬁned as the
mean value plus ﬁve SDs above the value for tumor
samples with aberrations in other genes.
Immunostaining for the MET Protein
The Bench-Mark XT automated slide processing sys-
tem (Ventana, Tucson, AZ) was used to stain for c-MET, as
previously described.30 In brief, after tissue sections weredeparafﬁnized using EZ Prep (Ventana), heat-induced
epitope retrieval with CC1 (Ventana) was performed
and the slides were incubated with primary antibodies
against c-MET (CONFIRM Anti-Total c-MET, clone SP44;
Ventana). Immunoreactivity was detected by using
the UltraView DAB Universal Detection Kit followed by
counter-staining with Hematoxylin II (Ventana) and
Bluing Reagent (Ventana). Immunopositive cases were
deﬁned as those exhibiting cytoplasmic and/or mem-
branous staining in more than 10% of cells.
Figure 2. Results for the validation cohort. The results for fresh frozen samples (A) and formalin-ﬁxed and parafﬁn-
embedded samples (B) are shown. (Upper) The reporter counts for the fusion probes are expressed as log2 (fusion probe
counts/threshold counts). Values are shown when the counting results were greater than the threshold. (Lower) The results
of 30 overexpression are expressed as log2 ratios (30/50 probe count ratio divided by the 30/50 probe count threshold).
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Test and Validation Cohorts
A total of 41 cases of LADC, with one aberrant
oncogenic transcript expressed in each, were selected
from 608 consecutive surgical cases and divided into
two cohorts (22 in the test cohort and 19 in the vali-
dation cohort). Samples were then examined in an MC
assay (see Fig. 1A). RNA from snap-frozen tissues from
the 22 test cohort samples had already been subjected
to whole transcriptome sequencing; therefore, each
RNA sample expressed 1 of the 36 aberrant transcripts
(see Table 1). RNA from snap-frozen tissues obtained
from the 19 validation cohort samples had been sub-
jected to RT-PCR; therefore, each RNA sample expressed
1 of the 36 aberrant transcripts.MC Assay to Determine the Expression of
Aberrant Oncogene Transcripts
The expression of 26 fusion transcripts and one
skipped MET transcript was ascertained by counting
the signals generated by the fusion probes alone.However, the fusion probes were not able to discrimi-
nate nine fusion transcripts that shared 50-partner gene
exons. In these cases, oncogene fusion was determined
from the results of fusion probe assays in conjunction
with the results from the 30/50 imbalance assays
(Fig. 1C).
The 22 test cohort cases expressed 13 aberrant
transcripts: 12 fusion transcripts and 1 exon 14-skipped
MET transcript (see Table 1). For 13 of the 22 cases, RNA
samples from snap-frozen tissues were available and
subjected to MC. The background counts were calculated
from data obtained for negative samples, and the
threshold count for each aberrant transcript was set as
the mean plus ﬁve SDs (as described in the Methods
section). Indeed, with these criteria, all 13 samples
were veriﬁed as log2 (fusion probe counts/threshold
counts) > 0, and the results of the imbalance assays for
the RET and NRG1 genes enabled us to judge KIF5B-RET_
(K15:R12) and CD74-ROS1 (C6:R34), respectively
(Supplementary Fig. 1A). The threshold values for the 39
FFPE samples were recalculated in the same way; the
results clearly distinguished between cases that were
Figure 2. (continued).
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(Supplementary Fig. 1B). The expression values deter-
mined by MC showed a good correlation with those
determined by RNA sequencing, thus indicating the
quantitative nature of the MC assay (Supplementary
Fig. 2).MC Assay of the Validation Cohort Samples
Next, the 19 cases in the validation cohort were
tested by MC assay using the same threshold values and
the criteria set from the test cohort. These cases
expressed 11 aberrant transcripts: 10 fusion transcripts
and one exon 14-skipped MET transcript (see Table 1).
The 19 cases yielded 10 RNA samples from snap-frozen
tissues and 18 from FFPE tissues. As expected, all 19cases were accurately judged as expressing aberrant
transcripts in both snap-frozen and FFPE samples
(Figs. 2A and 2B). In one NRG1 fusion–positive case (NR-
002), CD74_ex6 and CD74-NRG1 (C8:N6) were the major
transcripts detected. These results are consistent with
those obtained by RT-PCR, which showed that CD74-
NRG1 (C6:N6) was the minor transcript coexpressed
with CD74-NRG1 (C8:N6) as the major transcript in this
case.MC Assay of Nonsurgical Samples
The MC assay was then used to detect aberrant
transcripts in nonsurgical specimens that had been ob-
tained from the daily lung cancer clinic and used for
pathological diagnosis. Two FFPE transbronchial biopsy
Figure 3. Results for the nonsurgical samples. The results from the biopsy samples (A) and lavage samples (B) are shown. The
reporter counts of the fusion probes are expressed as log2 ratios (fusion probe counts/threshold counts). Values are shown
when the counting results were greater than the threshold.
210 Sunami et al Journal of Thoracic Oncology Vol. 11 No. 2specimens, which were diagnosed as CCDC6-RET and
CD74-ROS1 fusion by RT-PCR and ﬂuorescence in situ
hybridization, respectively, were subjected to MC. The
results clearly showed that these FFPE tissues were
positive for both of these fusions (see Fig. 3A). In addi-
tion, 18 bronchial lavage samples were also subjected to
MC analysis. The results showed that two EML4-ALK
fusion–positive samples had been diagnosed correctly
(see Fig. 3B).Discussion
Here, we describe an MC assay that allows multiplex
diagnosis of druggable aberrations for six oncogenes—
ALK, RET, ROS1, BRAF, and NRG1 fusions and MET exon
14 skipping—that are not detectable by NGS-based hot
spot sequencing of genomic DNA on account of the
highly diverse locations of the fusion and mutation
points. Samples that had already been identiﬁed as
either positive or negative were used to set the threshold
February 2016 Multiplex Diagnosis of Oncogenic Fusions 211values for the MC assay. The assay accurately diagnosed
aberrant expression of transcripts for the six druggable
oncogenes in both frozen and FFPE samples. These re-
sults demonstrate the utility of MC assay for detecting
gene fusions22,23 by increasing the number of oncogenes
examined to date. In addition, we showed that the MC
assay can be used to analyze nonsurgical specimens (e.g.,
samples obtained by transbronchial biopsy and bron-
choalveolar lavage samples) that are collected in the
daily lung cancer clinics and used for pathological diag-
nosis. Notably, the aberrations in the six oncogenes
examined in the present study were mutually exclusive;
they were also mutually exclusive with hot spot–
activating mutations in the EGFR, HER2, and BRAF on-
cogenes in our LADC cohort (Supplementary Fig. 3). The
high accuracy and robustness of the MC assay, even
when used with FFPE tumor tissues, indicate that it will
complement other diagnostic assays used to detect hot
spot EGFR, HER2, and BRAF oncogene mutations and
thereby improve the diagnosis of LADC. Other novel
druggable (but infrequent) oncogene fusions have been
identiﬁed in lung cancer.31–34 The fact that the probe set
used for the MC assay can be easily tailored to the genes
being examined is a great advantage. On the other hand,
the MC assay has a limitation in that it required a rela-
tively high amount of RNA (150 ng for frozen tissues and
400 ng for FFPE tissues), which means that it is not
applicable for samples from which an insufﬁcient
amount of RNA is obtained.
The present study also focused on MET exon 14
skipping, a novel druggable aberration that is being
examined in clinical trials as a therapeutic target.18,19
Among seven such cases, we found that two were nega-
tive after immunostaining FFPE tumor tissues for the
MET protein (Supplementary Table 2 and Supplementary
Fig. 4); therefore, immunostaining is not a suitable
method for detecting MET activation caused by exon
skipping. Aberrant RNA splicing associated with intronic
mutations may be a mechanism that drives carcinogen-
esis by activating oncogenes and inactivating tumor
suppressor genes. Thus, the MC assay will be suitable for
detecting aberrantly spliced transcripts as well as gene
fusions.
In summary, we have developed an assay that allows
simultaneous diagnosis of multiple druggable oncogene
aberrations in FFPE lung cancer tissues with a high de-
gree of accuracy and robustness. The advantage of this
assay is that probe sets can be changed easily to
accommodate changes in the genes being investigated.
The MC assay can be used not only to detect aberrant
transcripts but also to examine gene expression levels,
as exempliﬁed previously by PAM50, a Food and Drug
Administration–approved assay used to classify intrinsic
breast cancer subtypes.35 Thus, multiplexed assays thatsimultaneously detect aberrant transcripts and measure
the expression levels of other druggable genes are worth
developing.
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